By using MetaCore, Almac will be able to discover newbiomarkers and biological insights that may not be apparent from the literaturealone, Bryant says, and they can find pathway-based biomarkers that can be madeinto high-throughput arrays. These arrays can be used for applications rangingfrom preclinical to clinical to diagnostic.
While the deal is certainly important for Almac's work, italso marks growth in GeneGo's market base.
"Our products are gaining momentum in clinical diagnostics,both on the development side and among practitioners," Bryant says. "Almaccombines both as a highly reputable, scientific-oriented, new-generation CRO." The Almac Group comprises five closely integrateddivisions offering a broad range of global services from R&D,diagnostic/genomic services, API manufacture, formulation development, clinicaltrial supply and technology, and commercial-scale manufacture. Almac providesservices to over 600 companies including world leaders in the pharmaceuticaland biotech sectors. The company employs more than 1,16o people in Northern Ireland, nearly 160 in the United Kingdom and Ireland and more than 600 in the United States.
